Induction abrocitinib may prevent flare in moderate, severe
Induction therapy with abrocitinib was associated with low flare rates in patients with moderate to severe atopic dermatitis, according to a study.

The heterogeneous course of moderate to severe atopic dermatitis necessitates treatment flexibility.

This study evaluated maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, and response to treatment reintroduction following flare.

Patients with moderate to severe atopic dermatitis responding to open-label abrocitinib 200 mg monotherapy for 12 weeks were randomized 1:1:1 to blinded abrocitinib (200 mg or 100 mg) or placebo for 40 weeks. Patients experiencing flare received rescue treatment (abrocitinib 200 mg plus topical therapy).

-- Of 1233 patients, 798 responders to induction (64.7%) were randomized.

-- Flare probability during maintenance was 18.9%, 42.6%, and 80.9% with abrocitinib 200 mg, abrocitinib 100 mg, and placebo.

-- After rescue, 36.6%, 58.8%, and 81.6% of flaring patients regained IGA 0/1 response, and 55.0%, 74.5%, and 91.8% regained EASI-75 response in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups.

-- During maintenance, 63.2% and 54.0% of patients receiving abrocitinib 200 and 100 mg, respectively, experienced adverse events.

Conclusively, induction treatment with abrocitinib was effective; most responders continuing abrocitinib did not flare. Rescue treatment with abrocitinib plus topical therapy effectively recaptured response.